JAMP-CANDESARTAN TABLET

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

CANDESARTAN CILEXETIL

Доступно од:

JAMP PHARMA CORPORATION

АТЦ код:

C09CA06

INN (Међународно име):

CANDESARTAN

Дозирање:

32MG

Фармацеутски облик:

TABLET

Састав:

CANDESARTAN CILEXETIL 32MG

Пут администрације:

ORAL

Јединице у пакету:

15G/50G

Тип рецептора:

Prescription

Терапеутска област:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Резиме производа:

Active ingredient group (AIG) number: 0135220004; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2012-06-06

Карактеристике производа

1
PRODUCT MONOGRAPH
PR
JAMP-CANDESARTAN
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Angiotensin II
AT
1
Receptor Blocker
JAMP PHARMA CORPORATION
1310
rue
Nobel
Boucherville,
Québec J4B 5H3
Control No. : 229652
Date of Approval:
April 17, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE REACTIONS
..................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOSAGE AND
ADMINISTRATION.........................................................................
18
O V E R D O S A GE
..........................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................... 21
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
.................................................................................25
PHARMACEUTICAL INFORMATION
25
CLINICAL TRIALS
..........................................................................................................
26
DETAILED PHARMACOLOGY
.................................................................................
30
TO X IC OLO G Y
....................................................